Binimetinib, Pemetrexed and Cisplatin, Followed by Maintenance With Binimetinib and Pemetrexed, in Patients With Advanced Non-small Cell Lung Cancer NSCLC With KRAS Mutations. A Multicenter Phase IB Trial.
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Binimetinib (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Apr 2017 Status changed from not yet recruiting to recruiting.
- 21 Nov 2016 New trial record